News

Bonus Biogroup Welcomes Cell Therapy Expert Professor Horwitz

Bonus Biogroup Welcomes Cell Therapy Expert Professor Horwitz

Bonus Biogroup Strengthens Leadership with Key Appointment

Bonus Biogroup, a pioneering biotechnology company focused on immunomodulatory and regenerative mesenchymal stem cells (MSC), has made a significant move in its leadership by appointing Professor Edwin M. Horwitz, MD, PhD, as a member of its Advisory Board. This addition comes at a crucial time as the company prepares for Phase 3 clinical trials for its innovative therapeutic candidates, BonoFill™ and MesenCure™. BonoFill™ is an autologous tissue-engineered bone graft aimed at treating large or nonhealing bone defects, while MesenCure™ represents a groundbreaking allogeneic cell therapy designed to alleviate inflammation and facilitate tissue healing.

Expertise in Cell Therapy

Professor Horwitz brings a wealth of knowledge and experience to Bonus Biogroup, having spent over thirty years in the field of translational science, hematology, oncology, and stem cell therapy. His deep expertise in MSC biology and its clinical applications is highly regarded and aligns seamlessly with the company's objectives. According to Dr. Shai Meretzki, the company's Founder and CEO, Professor Horwitz's involvement demonstrates Bonus Biogroup's unwavering commitment to scientific excellence and innovation in the field of regenerative medicine.

A Vision for Regenerative Medicine

Speaking on his newly appointed role, Professor Horwitz expressed his excitement about contributing to Bonus Biogroup's mission. He emphasized the company's dedication to patient-centered therapies that address urgent clinical needs, which resonates with his own vision for the future of regenerative medicine. His innovative approach aims to unlock the full potential of cell-based treatments, further enhancing the quality of life for patients worldwide.

Current Roles and Contributions

In addition to his new advisory role, Professor Horwitz holds significant academic positions at the Emory University School of Medicine as the Marcus Professor of Cellular Therapy. He also directs Transplantation Biology and Therapeutics at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta. His involvement in the academic community and as Editor-in-Chief of Cytotherapy highlights his influence and dedication to advancing cell and gene therapy.

Innovative Products at Bonus Biogroup

Bonus Biogroup is at the forefront of developing groundbreaking therapies aimed at improving patient outcomes. Their proprietary product, BonoFill™, serves as a tissue-engineered human bone graft that utilizes autologous cells to enhance safety and reduce rejection risks. Cultivated in a bioreactor on a 3D scaffold, BonoFill™ demonstrates a remarkable 90% success rate in treating bone deficiencies in clinical trials. As they gear up for a Phase 3 study set for the near future, the anticipated market potential for BonoFill™ within orthopedic and craniomaxillofacial applications could reach around $25 billion by 2030.

MesenCure™: Addressing Critical Health Challenges

Bonus Biogroup’s MesenCure™ targets critical health issues such as inflammation and tissue damage, with ongoing research showing promising results. In a Phase 2 trial, MesenCure™ showcased a 68% reduction in mortality among patients suffering from severe respiratory distress due to pneumonia, significantly improving recovery outcomes. The recent FDA clearance to initiate a Phase 3 trial for broader indications emphasizes the urgency and importance of bringing this treatment to market. The company anticipates a market potential of $9.4 billion for treating acute respiratory distress syndrome (ARDS) by 2030.

About Bonus Biogroup

Bonus Biogroup Ltd. is a biotechnology enterprise innovating in the field of regenerative medicine. The company focuses on creating cutting-edge therapies that apply advanced technologies to regenerate cells and tissue. Their extensive intellectual property portfolio, composed of numerous patents, supports the ongoing development of their clinical-stage and preclinical products, showcasing a commitment to safe and effective therapeutic solutions. The company aims to enhance the accessibility of these innovations while addressing conditions with significant unmet medical needs.

Frequently Asked Questions

1. Who is Professor Edwin M. Horwitz?

Professor Edwin M. Horwitz is a renowned expert in cell therapy with over three decades of experience in the fields of hematology, oncology, and stem cell research.

2. What is Bonus Biogroup's focus?

Bonus Biogroup specializes in immunomodulatory and regenerative mesenchymal stem cells to develop innovative therapies for tissue engineering and cell therapy.

3. What are the key products of Bonus Biogroup?

The key products under development are BonoFill™, an autologous tissue-engineered bone graft, and MesenCure™, an allogeneic cell therapy targeting inflammation and tissue damage.

4. What are the expected market potentials of BonoFill™ and MesenCure™?

The market potential for BonoFill™ is estimated at $25 billion by 2030, while MesenCure™ could reach approximately $9.4 billion for treating ARDS.

5. How does Professor Horwitz contribute to Bonus Biogroup?

Professor Horwitz provides expertise in MSC biology and clinical applications, guiding the company's clinical programs and strategic direction in regenerative medicine.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Zoomlion Boosts Mining Gear Amid Global Revenue Surge

Updated Category News Views 4

An Ambitious Expansion Overhaul Alright, let's talk Zoomlion Heavy Industry Science & Technology Co., Ltd. They're not just making a splash; they're wading knee-deep into expanding their mining machinery operations and taking charge in international markets. You see, in the first half of 2026, this Chinese behemoth saw its mining machinery business skyrocket by over...

Continue Reading
Arrvel's Thermal Printers: Aiming at E-Com Sellers

Updated Category News Views 4

Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...

Continue Reading
Young Visionaries Win Junior Medals at STARMUS VIII

Updated Category News Views 5

Fresh from the Canary Islands' shores, STARMUS VIII has lifted the veil on two young powerhouses shaping tomorrow—Valeria Corrales and Aneeshwar Kunchala. These two have snagged coveted honors, crowning them as champions of their generation. Igniting Passion for Science and the Environment Valeria Corrales isn't just another face in the crowd; she’s the force behind a...

Continue Reading
Kexing Biopharm Expands Global Reach at CPHI Milan

Updated Category News Views 8

Kexing Biopharm's Showstopper Moment in Milan Call it a strategic blowout or just audacious timing—Kexing Biopharm's move at the CPHI Milan 2026 has painted a clear picture. From October 6th to 8th, Milan was the stage where Kexing rolled out its showcase, bragging about a pipeline that screams innovation and possibility. And let’s be honest, their timing couldn’t...

Continue Reading
AI Revenue Missteps Shake Semiconductor Stocks

Updated Category News Views 2

Nervous Times for Semiconductor Stocks When the semiconductor sector started October like a high-speed train, I thought we might sail through this month without hitting turbulence. But then, in trotted some shaky AI revenue numbers, and bam, the whole sector took a hit off its October highs. The semiconductor stocks, led by giants like Taiwan Semiconductor Manufacturing...

Continue Reading
Haag-Streit Debuts Innovative Octopus 910 Perimeter at AAO

Updated Category News Views 2

Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...

Continue Reading
Phoenix Scholar Examines AI and Institutional Trust

Updated Category News Views 3

A Thoughtful Look at Trust and Technology We're staring at an issue here that dives deep into the guts of how technology, AI in particular, is reshaping our professional landscape. The latest issue of the Phoenix Scholar, a publication from the University of Phoenix College of Doctoral Studies, is tackling big questions. It's that kind of brainy reading where you untangle...

Continue Reading
tm:rw Revolutionizes Retail with Live TikTok Studios

Updated Category News Views 3

tm:rw Takes a Bold Step into Social Commerce Throw out whatever you've thought about traditional brick-and-mortar retail because tm:rw isn't just bending the rules—it's burning the book. Launching nine branded studio spaces at their Times Square flagship, tm:rw is blending live streaming with in-person shopping, all in sync with TikTok Shop. The experience is less about...

Continue Reading
Amap, Sands China Unleash Tutu Robots for Resort Duty

Updated Category News Views 4

Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...

Continue Reading
KAPSARC Drives Energy Dialogue at WPC in Riyadh

Updated Category News Views 3

Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...

Continue Reading

Top 5 Most Recently Viewed Articles

Joanne Crevoiserat's Strategic Move with Tapestry Shares

Updated Category News Views 138

Joanne Crevoiserat's Insider Activity at Tapestry A notable insider transaction has come to light recently, marking a significant moment for Tapestry (NYSE: TPR). Joanne Crevoiserat, Tapestry's Chief Executive Officer, executed an options exercise that reveals both a strategic financial decision and a substantial investment in the company's future. Details of the...

Continue Reading
Investors Urged to Act: Integral Ad Science Class Action Alert

Updated Category News Views 125

Integral Ad Science Class Action Update Integral Ad Science Holding Corp. (NASDAQ: IAS) is currently facing a class action lawsuit that affects numerous investors. A free shareholder information service has alerted those with losses exceeding $100,000 to take action before the lead plaintiff application deadline. Time-Sensitive Legal Actions Investors should be aware that...

Continue Reading
KBRA Ratings Announced for New Citigroup Mortgage Trust

Updated Category News Views 296

KBRA Assigns Preliminary Ratings to Citigroup Mortgage Loan Trust 2025-INV1 KBRA has recently assigned preliminary ratings to 62 classes of mortgage pass-through certificates associated with Citigroup Mortgage Loan Trust 2025-INV1 (CMLTI 2025-INV1). This residential mortgage-backed securities transaction boasts a significant backing of non-owner occupied investor...

Continue Reading
Netflix Enters Podcast World with iHeartMedia Partnership

Updated Category News Views 115

Introduction to the Partnership Netflix, Inc. (NASDAQ: NFLX) is expanding its content offerings in an exciting new direction. In a recent announcement, Netflix joined forces with iHeartMedia, Inc. (NASDAQ: IHRT) to launch a unique video podcasting deal. This collaboration marks a significant shift in how audiences will engage with podcasts, as iHeart's most beloved shows...

Continue Reading
Hansa Biopharma's Q3 Success and Future Growth Plans

Updated Category News Views 201

Hansa Biopharma's Promising Quarter Hansa Biopharma AB, a trailblazer in the development of essential treatments for rare immunological conditions, recently shared its third-quarter and interim financial results for 2025. The report highlighted significant advancements in its clinical trials and a strong financial performance that underscores the company's growth...

Continue Reading